Group 1 - Junshi Bioscience (01877) shares rose over 10%, currently up 11.03% at HKD 34.22, with a trading volume of HKD 516 million [1] - The company announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, a "dual" recombinant protein vaccine aimed at preventing monkeypox virus infection [1] - Preclinical studies indicate that JT118 shows significant protective effects against vaccinia virus/monkeypox virus infections in small animal models, with good safety profiles [1] Group 2 - The 2025 World Lung Cancer Conference (WCLC) will be held from September 6 to 9, 2025, in Barcelona, Spain [1] - Junshi Bioscience's innovative products, including anti-BTLA monoclonal antibody tifcemalimab and anti-PD-1 monoclonal antibody teriprizumab, have multiple research results selected for oral presentations and posters at the conference, showcasing the latest advancements in lung cancer research [1]